|
| 35021603 | Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. | Haematologica | 2023 |
| 37668976 | Inhibitor Library Screening of SH2 Domains Through Denaturation-Based Assays. | Methods Mol Biol | 2023 |
| 37711592 | Medicinal chemistry advances in targeting class I histone deacetylases. | Explor Target Antitumor Ther | 2023 |
| 37588188 | Monogenic deficiency in murine intestinal Cdc42 leads to mucosal inflammation that induces crypt dysplasia. | Genes Dis | 2023 |
| 37573301 | STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway. | Mol Cancer | 2023 |
| 37726279 | ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. | Nat Commun | 2023 |
| 35229974 | JAK-STAT core cancer pathway: An integrative cancer interactome analysis. | J Cell Mol Med | 2022 |
| 36045346 | PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma. | Mol Cancer | 2022 |
| 36341492 | Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma. | EMBO Mol Med | 2022 |
| 36355493 | High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. | Pharmaceuticals (Basel) | 2022 |
| 32929218 | TYK2 licenses non-canonical inflammasome activation during endotoxemia. | Cell Death Differ | 2021 |
| 33623882 | Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. | Hemasphere | 2021 |
| 33482575 | A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation. | Cytokine | 2021 |
| 34944832 | The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. | Cancers (Basel) | 2021 |
| 34944800 | Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia. | Cancers (Basel) | 2021 |
| 34885151 | Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer. | Cancers (Basel) | 2021 |
| 34957277 | Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. | Front Vet Sci | 2021 |
| 34818373 | Adipocyte STAT5 deficiency does not affect blood glucose homeostasis in obese mice. | PLoS One | 2021 |
| 34547241 | A hydride transfer complex reprograms NAD metabolism and bypasses senescence. | Mol Cell | 2021 |
| 34680385 | A Recurrent <i>STAT5B<sup>N642H</sup></i> Driver Mutation in Feline Alimentary T Cell Lymphoma. | Cancers (Basel) | 2021 |
| 34101461 | Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. | J Med Chem | 2021 |
| 34075200 | STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. | Leukemia | 2021 |
| 34298678 | Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. | Cancers (Basel) | 2021 |
| 34320169 | A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. | Blood | 2021 |
| 34233950 | Down-regulation of A20 promotes immune escape of lung adenocarcinomas. | Sci Transl Med | 2021 |
| 33465556 | Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. | Neoplasia | 2021 |
| 33034050 | Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer. | Int J Cancer | 2021 |
| 33323974 | STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway. | Oncogene | 2021 |
| 31123029 | High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. | Haematologica | 2020 |
| 31667643 | Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. | Angiogenesis | 2020 |
| 32081369 | Corrigendum to High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 [Translational Oncology Volume 12, Issue 2, February 2019, Pages 256-268]. | Transl Oncol | 2020 |
| 33301031 | Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. | Blood | 2020 |
| 32665700 | Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. | Leukemia | 2020 |
| 32707820 | Targeting STAT3 and STAT5 in Cancer. | Cancers (Basel) | 2020 |
| 32281944 | The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5. | J Clin Invest | 2020 |
| 32473405 | STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue. | Mol Metab | 2020 |
| 32326377 | STAT5 is Expressed in CD34[+]/CD38[-] Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. | Cancers (Basel) | 2020 |
| 32227030 | Advances in covalent kinase inhibitors. | Chem Soc Rev | 2020 |
| 32344427 | CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. | Blood | 2020 |
| 30439626 | High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. | Transl Oncol | 2019 |
| 31817042 | Direct Targeting Options for STAT3 and STAT5 in Cancer. | Cancers (Basel) | 2019 |
| 31784108 | Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. | Immunity | 2019 |
| 31717342 | Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. | Cancers (Basel) | 2019 |
| 30131584 | Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. | Leukemia | 2019 |
| 31270081 | STAT3β is a tumor suppressor in acute myeloid leukemia. | Blood Adv | 2019 |
| 31269779 | STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice. | Cancers (Basel) | 2019 |
| 31175292 | Structural and functional consequences of the STAT5B<sup>N642H</sup> driver mutation. | Nat Commun | 2019 |
| 31407334 | JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. | Int J Cancer | 2019 |
| 31406155 | Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. | Cell Death Dis | 2019 |
| 31575669 | The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis. | Haematologica | 2019 |